CCHE Seminar Series: Utilization of Real-World Evidence in Reimbursement Decision-Making: Challenges and Solutions
Utilization of Real-World Evidence in Reimbursement Decision-Making: Challenges and Solutions
Friday October 22, 2021, 10am-12pm, Zoom
Abstract: Reimbursement decision-making plays a critical role in patient treatment access. Different from trial evidence used for the market authorizations of new drugs, real-world evidence (RWE) is required to reduce the uncertainty and bias in reimbursement decision-making. However, utilizing RWE in reimbursement decision-making is often challenged and criticized due to the lack of robust and unbiased RWE. In this seminar, Dr. Wendong Chen will share the experiences of Normin Health in the last 10 years regarding the challenges and solutions of utilizing RWE to support the reimbursement submissions of new treatments in China.
Dr. Wendong Chen obtained his MD from Beijing Medical University in 1996 and his Ph.D. in health economics at the University of Toronto in 2010. Dr. Wendong Chen is the founder of Normin Health and worked for three years at the University of Copenhagen for evidence-based medicine. He has authored over 40 publications in health outcomes and economic research related to cancers (lung cancer, breast cancer, prostate cancer, multiple myeloma), chronic diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, chronic viral hepatitis), and medical devices (hemostatic agents, vena cave filters, and staplers). The academic affiliations of Dr. Wendong Chen include the Toronto Health Economics and Technology Assessment Collaborative at the University of Toronto (Investigator), the Cancer Center of Second Xiangya Hospital at the Central South University (Specially appointed professor), and Guizhou Medical University (graduate mentor).